Shots:
Takeda has presented the P-III (LATITUDE) studies data assessing zasocitinib (TAK-279) in adults with mod. to sev. plaque psoriasis (PsO) at EADV’26
In P-III (LATITUDE Atlas) study, zasocitinib was superior to deucravacitinib across 1 & all key 2EPs, with complete skin clearance emerging as early as Wk. 8 & 36.5% vs 13.9% pts achieving…
